Screening for Mild Cognitive Impairment Using the Dementia Rating Scale-2

Area of Science:

• Neuroscience
• Gerontology
• Cognitive Psychology

Background:

• Mild cognitive impairment (MCI) is a transitional stage between healthy aging and Alzheimer's disease (AD).
• Accurate differentiation of MCI from AD and healthy controls (HCs) is crucial for timely intervention.
• The Dementia Rating Scale-2 (DRS-2) is a widely used neuropsychological assessment tool.

Purpose of the Study:

• To evaluate the diagnostic accuracy of the DRS-2 in distinguishing between HCs, individuals with MCI, and patients with AD.
• To determine the sensitivity and specificity of the DRS-2 for various diagnostic comparisons.

Main Methods:

• A cohort of 50 HCs, 98 individuals with MCI, and 49 patients with AD underwent neurological examination and neuropsychological testing, including the DRS-2.
• Performance on DRS-2 subscales was compared across the three groups.
• Receiver operating characteristic (ROC) analysis was implicitly used to determine optimal cutoffs for sensitivity and specificity.

Main Results:

• Patients with AD generally scored lower on the DRS-2 than individuals with MCI, who in turn scored lower than HCs.
• No significant difference was observed between MCI and HCs on the construction subscale.
• The DRS-2 demonstrated good diagnostic performance: e.g., 71% sensitivity and 86% specificity for MCI vs. HCs at a cutoff of 136.

Conclusions:

• The DRS-2 is a valuable, easily administered cognitive screening tool.
• Its sensitivity and specificity support its utility in aiding the detection and differentiation of MCI.
• The DRS-2 can assist clinicians in identifying individuals who may benefit from further diagnostic evaluation for cognitive decline.